GVI
VRTX icon

Green Valley Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

Green Valley Investors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$52.1M Buy
307,761
+102,505
+50% +$18.1M 2.96% 13
2019
Q2 		$37.6M Sell
205,256
-34,265
-14% -$5.99M 2.14% 19
2019
Q1 		$44.1M Hold
239,521
– – 2.25% 19
2018
Q4 		$39.7M Sell
239,521
-61
-0% -$10.6K 2.28% 18
2018
Q3 		$46.2M Sell
239,582
-18,837
-7% -$3.35M 2.06% 18
2018
Q2 		$43.9M Sell
258,419
-18,235
-7% -$2.83M 2.06% 19
2018
Q1 		$45.1M Buy
276,654
+156,400
+130% +$25.5M 2.15% 16
2017
Q4 		$18M Sell
120,254
-9,490
-7% -$1.41M 0.86% 27
2017
Q3 		$19.7M Sell
129,744
-55,686
-30% -$8.38M 0.96% 26
2017
Q2 		$23.9M Sell
185,430
-7,271
-4% -$875K 1.16% 25
2017
Q1 		$21.1M Sell
192,701
-2,576
-1% -$227K 1.04% 26
2016
Q4 		$14.4M Sell
195,277
-40,398
-17% -$3.29M 0.76% 27
2016
Q3 		$20.6M Sell
235,675
-105,855
-31% -$10M 1.05% 23
2016
Q2 		$29.4M Sell
341,530
-117,768
-26% -$10.2M 0.9% 25
2016
Q1 		$36.5M Sell
459,298
-40,702
-8% -$3.68M 0.89% 23
2015
Q4 		$62.9M Hold
500,000
– – 1.29% 23
2015
Q3 		$52.1M Hold
500,000
– – 1.12% 23
2015
Q2 		$61.7M Hold
500,000
– – 1.19% 25
2015
Q1 		$59M Hold
500,000
– – 1.18% 23
2014
Q4 		$59.4M Hold
500,000
– – 1.25% 24
2014
Q3 		$56.2M Hold
500,000
– – 1.28% 23
2014
Q2 		$47.3M Sell
500,000
-500,000
-50% -$35.1M 1.1% 25
2014
Q1 		$70.7M Sell
1,000,000
-791,786
-44% -$62.7M 1.62% 24
2013
Q4 		$133M Hold
1,791,786
– – 2.9% 16
2013
Q3 		$136M Sell
1,791,786
-708,214
-28% -$56.4M 3.34% 14
2013
Q2 		$200M Buy
+2,500,000
New +$184M 4.89% 6

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Green Valley Investors's VRTX Position: Q3 2019 in Review

Green Valley Investors increased its Vertex Pharmaceuticals (VRTX) stake by 50% in Q3 2019, buying an estimated $18.1M and bringing the position to 307,761 shares worth $52.1M. The position accounts for 2.96% of the portfolio, ranked #13.

Green Valley Investors first reported a position in VRTX in Q2 2013 and has held it in 26 quarters since. The position peaked at $200M in Q2 2013. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

  • Green Valley Investors held 307,761 shares of Vertex Pharmaceuticals worth $52.1M as of Q3 2019.
  • Green Valley Investors bought 102,505 Vertex Pharmaceuticals shares in Q3 2019, an estimated $18.1M.
  • Vertex Pharmaceuticals made up 2.96% of Green Valley Investors's portfolio in Q3 2019, its #13 holding.
  • Green Valley Investors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • Green Valley Investors's Vertex Pharmaceuticals position peaked at $200M in Q2 2013.
  • 708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Green Valley Investors's 13F filing for Q3 2019, filed 13 Nov 2019.